Splenic extramedullary hematopoietic proliferation in Philadelphia chromosome-negative myeloproliferative neoplasms: Heterogeneous morphology and cytological composition

Modern Pathology

Volumn 25, Issue 6, 2012, Pages 815-827

  Prakash, Sonam ^a   Hoffman, Ronald ^b   Barouk, Sharon ^a   Wang, Y Lynn ^a   Knowles, Daniel M ^a   Orazi, Attilio ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

extramedullary hematopoiesis; myeloproliferative neoplasms; spleen

Indexed keywords

CD34 ANTIBODY; CD8 ANTIGEN; GLYCOPHORIN C; GLYCOPROTEIN IB ALPHA; NERVE GROWTH FACTOR RECEPTOR; SMOOTH MUSCLE ACTIN; STEM CELL FACTOR RECEPTOR;

ADULT; AGED; ARTICLE; CELL PROLIFERATION; CLINICAL ARTICLE; ERYTHROPOIESIS; EXTRAMEDULLARY HEMATOPOIETIC PROLIFERATION; FEMALE; FOLLOW UP; GRANULOPOIESIS; HEMATOPOIETIC CELL; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; MEGAKARYOPOIESIS; MYELOFIBROSIS; MYELOPROLIFERATIVE DISORDER; PHILADELPHIA 1 CHROMOSOME; PHILADELPHIA CHROMOSOME NEGATIVE MYELOPROLIFERATIVE NEOPLASM; POLYCYTHEMIA VERA; PRIORITY JOURNAL; SPLENECTOMY;

ADULT; AGED; AGED, 80 AND OVER; BIOPSY; FEMALE; HEMATOPOIESIS, EXTRAMEDULLARY; HUMANS; IMMUNOHISTOCHEMISTRY; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; NEOPLASM STAGING; NEW YORK CITY; PHILADELPHIA CHROMOSOME; POLYCYTHEMIA VERA; PRIMARY MYELOFIBROSIS; SPLEEN; SPLENECTOMY; TIME FACTORS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 84862830695     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.2012.33     Document Type: Article

References (27)

1. Thiele J, Klein H, Falk S, et al. Splenic megakaryocytopoiesis in primary (idiopathic) osteomyelofibrosis. An immunohistological and morphometric study with comparison of corresponding bone marrow features. Acta Haematol 1992;87:176-180.
2. Thiele J, Kvasnicka HM, Orazi A. Bone marrow histopathology in myeloproliferative disorders-current diagnostic approach. Semin Hematol 2005; 42:184-195. (Pubitemid 41400660)
3. Lataillade JJ, Pierre-Louis O, Hasselbalch HC, et al. Does primary myelofibrosis involve a defective stem cell niche? From concept to evidence. Blood 2008; 112:3026-3035.
4. Bogani C, Ponziani V, Guglielmelli P, et al. Hypermethylation of CXCR4 promoter in CD34+ cells from patients with primary myelofibrosis. Stem Cells 2008;26:1920-1930.
5. Cho SY, Xu M, Roboz J, et al. The effect of CXCL12 processing on CD34+ cell migration in myeloproliferative neoplasms. Cancer Res 2010;70:3402-3410.
6. O'Malley DP, Orazi A, Wang M, Cheng L. Analysis of loss of heterozygosity and X chromosome inactivation in spleens with myeloproliferative disorders and acute myeloid leukemia. Mod Pathol 2005a;18: 1562-1568. (Pubitemid 41670654)
7. Konoplev S, Hsieh PP, Chang CC, et al. Janus kinase 2 V617F mutation is detectable in spleen of patients with chronic myeloproliferative diseases suggesting a malignant nature of splenic extramedullary hematopoiesis. Hum Pathol 2007;38:1760-1763. (Pubitemid 350179922)
8. Hsieh PP, Olsen RJ, O'Malley DP, et al. The role of Janus Kinase 2 V617F mutation in extramedullary hematopoiesis of the spleen in neoplastic myeloid disorders. Mod Pathol 2007;20:929-935. (Pubitemid 47271886)
9. O'Malley DP, Kim YS, Perkins SL, et al. Morphologic and immunohistochemical evaluation of splenic hematopoietic proliferations in neoplastic and benign disorders. Mod Pathol 2005b;18:1550-1561. (Pubitemid 41670653)
10. Porcu P, Neiman RS, Orazi A. Splenectomy in agnogenic myeloid metaplasia. Blood 1999;93: 2132-2134.
11. Mesa RA, Li CY, Schroeder G, Tefferi A. Clinical correlates of splenic histopathology and splenic karyotype in myelofibrosis with myeloid metaplasia. Blood 2001;97:3665-3667.
12. Chen Q, Lu P, Jones AV, et al. Amplification refractory mutation system, a highly sensitive and simple polymerase chain reaction assay, for the detection of JAK2 V617F mutation in chronic myeloproliferative disorders. J Mol Diagn 2007;9:272-276. (Pubitemid 47305096)
13. Swerdlow SH, Campo E, Harris NL, et al. (eds.) WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. IARC: Lyon, 2008.
14. Remstein ED, Kurtin PJ, Nascimento AG. Sclerosing extramedullary hematopoietic tumor in chronic myeloproliferative disorders. Am J Surg Pathol 2000; 24:51-55. (Pubitemid 30033396)
15. Levine RL, Wadleigh M, Cools J, et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 2005;7: 387-397. (Pubitemid 40544655)
16. James C, Ugo V, Le Couedic JP, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 2005;434: 1144-1148. (Pubitemid 40663494)
17. Baxter EJ, Scott LM, Campbell PJ, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 2005;365: 1054-1061. (Pubitemid 40386783)
18. Kralovics R, Passamonti F, Buser AS, et al. A gain-offunction mutation of JAK2 in myeloproliferative disorders. N Engl J Med 2005;352:1779-1790. (Pubitemid 40570926)
19. Beer PA, Delhommeau F, LeCouedic JP, et al. Two routes to leukemic transformation after a JAK2 mutation- positive myeloproliferative neoplasm. Blood 2010;115:2891-2900.
20. Abdel-Wahab O, Manshouri T, Patel J, et al. Genetic analysis of transforming events that convert chronic myeloproliferative neoplasms to leukemias. Cancer Res 2010;70:447-452.
21. Tefferi A. Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1. Leukemia 2010;24:1128-1138.
22. Pardanani A, Lasho T, Finke C, et al. LNK mutation studies in blast-phase myeloproliferative neoplasms, and in chronic-phase disease with TET2, IDH, JAK2 or MPL mutations. Leukemia 2010;24: 1713-1718.
23. Thoennissen NH, Krug UO, Lee DH, et al. Prevalence and prognostic impact of allelic imbalances associated with leukemic transformation of Philadelphia chromosome- negative myeloproliferative neoplasms. Blood 2010;115:2882-2890.
24. Hussein K, Pardanani AD, Van Dyke DL, et al. International Prognostic Scoring System-independent cytogenetic risk categorization in primary myelofibrosis. Blood 2010;115:496-499.
25. Tam CS, Abruzzo LV, Lin KI, et al. The role of cytogenetic abnormalities as a prognostic marker in primary myelofibrosis: applicability at the time of diagnosis and later during disease course. Blood 2009;113:4171-4178.
26. Migliaccio AR, Martelli F, Verrucci M, et al. Altered SDF-1/CXCR4 axis in patients with primary myelofibrosis and in the Gata1 low mouse model of the disease. Exp Hematol 2008;36:158-171.
27. Ghinassi B, Martelli F, Verrucci M, et al. Evidence for organ-specific stem cell microenvironments. J Cell Physiol 2010;223:460-470.